Connection

Campbell McInnes to Models, Molecular

This is a "connection" page, showing publications Campbell McInnes has written about Models, Molecular.
Connection Strength

1.344
  1. Improved lead-finding for kinase targets using high-throughput docking. Curr Opin Drug Discov Devel. 2006 May; 9(3):339-47.
    View in: PubMed
    Score: 0.231
  2. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022 02 24; 65(4):3420-3433.
    View in: PubMed
    Score: 0.172
  3. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity. J Med Chem. 2015 Jan 08; 58(1):433-42.
    View in: PubMed
    Score: 0.105
  4. Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor a and ? subtypes: a molecular modeling study. PLoS One. 2013; 8(9):e74615.
    View in: PubMed
    Score: 0.096
  5. Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly. J Med Chem. 2013 Feb 28; 56(4):1573-82.
    View in: PubMed
    Score: 0.092
  6. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol. 2010 Dec 17; 5(12):1169-82.
    View in: PubMed
    Score: 0.078
  7. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem Pharmacol. 2009 May 15; 77(10):1561-71.
    View in: PubMed
    Score: 0.069
  8. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov; 2(11):608-17.
    View in: PubMed
    Score: 0.059
  9. Catch the kinase conformer. Chem Biol. 2006 Jul; 13(7):693-4.
    View in: PubMed
    Score: 0.058
  10. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle. IDrugs. 2006 Apr; 9(4):273-8.
    View in: PubMed
    Score: 0.057
  11. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol. 2004 Apr; 11(4):525-34.
    View in: PubMed
    Score: 0.050
  12. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents. 2003 Jan; 3(1):57-69.
    View in: PubMed
    Score: 0.046
  13. Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2016 11 15; 26(22):5573-5579.
    View in: PubMed
    Score: 0.030
  14. Calpain 10 homology modeling with CYGAK and increased lipophilicity leads to greater potency and efficacy in cells. ACS Chem Biol. 2012 Aug 17; 7(8):1410-9.
    View in: PubMed
    Score: 0.022
  15. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. 2010 Jun 10; 53(11):4367-78.
    View in: PubMed
    Score: 0.019
  16. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors. J Med Chem. 2010 Mar 11; 53(5):2136-45.
    View in: PubMed
    Score: 0.019
  17. Functional characterization of the RAD51D E233G genetic variant. Pharmacogenet Genomics. 2009 Feb; 19(2):153-60.
    View in: PubMed
    Score: 0.017
  18. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
    View in: PubMed
    Score: 0.017
  19. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design. Chem Biol. 2006 Feb; 13(2):201-11.
    View in: PubMed
    Score: 0.014
  20. Protein structures in virtual screening: a case study with CDK2. J Med Chem. 2006 Jan 12; 49(1):92-104.
    View in: PubMed
    Score: 0.014
  21. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol. 2005 Jul 15; 350(3):587-98.
    View in: PubMed
    Score: 0.014
  22. Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A. 2005 Feb 08; 102(6):1871-6.
    View in: PubMed
    Score: 0.013
  23. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org Biomol Chem. 2004 Oct 07; 2(19):2735-41.
    View in: PubMed
    Score: 0.013
  24. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorg Med Chem Lett. 2004 Aug 16; 14(16):4237-40.
    View in: PubMed
    Score: 0.013
  25. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure. 2003 Dec; 11(12):1537-46.
    View in: PubMed
    Score: 0.012
  26. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure. 2003 Apr; 11(4):399-410.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.